Miranda J. Toledano
Independent DirectorMs. Miranda J. Toledano, M.B.A. serves as Chief Executive Officer of Entera Bio Ltd. since July 15, 2022. She serves as an Independent Director of Journey Medical Corporation since June 2021. She served as a Director of LipoMedix Pharmaceutical Inc. Ms. Toledano served as Independent Director at NEXGEL, Inc. since September 9, 2021 until March 31, 2024. She was an Independent Director of Compass Therapeutics, Inc since June 25, 2021 until May 2022. She serves as Director of Entera Bio Ltd. She served as Independent External Director at Entera Bio Ltd. since September 27, 2018 and served as its Chief Business Officer, Head of Corporate Strategy since May 16, 2022 until July 2022 and served as Chief Financial Officer of Entera Bio Ltd since May 16, 2022 until July 15, 2022 and has also served as a Member of the Board since September 2018, as a Member of the Scientific Advisory Committee of the Board since February 2022. Ms. Toledano is a Member of the Board of Journey Medical and Lipomedix. She was a Managing Director for VelocityHealth Securities, Inc. and is based Tel Aviv. She serves as Member of Board of Directors of Lipomedix Pharmaceuticals Limited from 1998 to 2003, Ms. Toledano served as Head of Healthcare Investment Banking at MLV & Co. now an FBR company. Previously, Ms. Toledano served as Chief Operating Officer, Chief Financial Officer and Director of TRIGR Therapeutics, an oncology focused, clinical stage bispecific antibody company acquired by Compass Therapeutics in June 2021. At TRIGR, Ms. Toledano oversaw the clinical development of lead asset TR009 (now CTX-009) and led strategic execution, including China License Transaction and acquisition by CMPX. Ms. Toledano served as Chief Operating Officer, Chief Financial Officer and Board Member at TRIGR Therapeutics from August 2018 to June 2021, where she oversaw the clinical development and led strategic execution. Ms. Toledano served on the executive management team of Sorrento Therapeutics (Nasdaq: SRNE) as EVP Corporate Development from September 2016 until August 2017. From 2012 to 2016, Ms. Toledano served as Head of Healthcare Investment Banking at MLV & Co. (acquired by B. Riley FBR & Co.), where she completed biotech equity financings (IPOs, ATMs and follow-ons). Prior to joining MLV, from 2004 until 2010, Ms. Toledano served as Vice President in the investment group of Royalty Pharma. From 1998 to 2003, Ms. Toledano developed and served as Senior Manager in the life science corporate finance group at Ernst & Young (Israel). Ms. Toledano holds a Master of Business Administration degree in Finance and Entrepreneurship from New York University's Stern School of Business, as well as a Bachelor of Arts degree in Economics from Tufts University.
Positions
- Company NameJourney Medical CorporationStock CodeDERMPositionIndependent DirectorColleagues
- LALindsay Allan RosenwaldExecutive Chairman
- CMClaude MaraouiFounder, President, CEO & Director
- JMJoseph M. BeneschCFO & Corporate Controller
- RARamsey AlloushCOO, General Counsel & Company Secretary
- BPBrian ProutExecutive Director of Marketing
- NHNeil HerskowitzIndependent Director
- JSJustin SmithIndependent Director
- Company NameEntera Bio Ltd.Stock CodeENTXPositionCEO & DirectorColleagues
- MJMiranda J. ToledanoCEO & Director
- GJGeno J. GermanoIndependent Chairman
- HGHillel GalitzerChief Operating Officer
- GBGregory BurshteinChief of Research & Development
- DYDana Yaacov-GarbeliChief Financial Officer
- RBRachel B. WagmanChief Clinical Advisor
- FCFelicia CosmanChairman of Scientific Advisory Board & Chief Clinical Advisor (Endocrinology)
- HTHaya TaitelNon-Employee Independent Director
- SDSteven D. RubinIndependent Director
